The biphasic pattern of age-specific malignant brain tumor mortality rates
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Article abstract Many aging-associated neurologic disorders, including primary malignant brain tumors (MBT), share a common biphasic age-specific mortality rate pattern: initially increasing exponentially with age, and then declining. A modeling study using MBT mortality was conducted to determine if the observed biphasic pattern of MBT age-specific mortality rates emerges if one assumes that there exists a population subset that is inherently susceptible to MBT, and that the risk of mortality from MBT in that susceptible population subset continues to increase exponentially with age. A hypothetical population was subjected to 1988 general mortality risks. A population subset susceptible to MBT was subjected to both exponentially increasing 1988 general and MBT mortality risks. Expected MBT age-specific mortality rates in the total population (both general and MBT susceptible subsets) were determined. Expected MBT age-specific mortality rates in the total population initially increase exponentially with age, and then decline. Moreover, when the size of the MBT-susceptible population subset was set at 1/125 of the size of the general population size, the modeled pattern of age-specific MBT mortality rates closely mimicked the observed pattern of age-specific MBT mortality rates. The observed biphasic pattern of age-specific MBT mortality rates can be explained by the existence of an MBT-susceptible population subset in whom the risk of MBT mortality increases exponentially with age and population subset depletion occurs.
- Received January 24, 2000.
- Accepted in final form June 12, 2000.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
ARTICLES
Epidemiologic observations on Parkinson's diseaseIncidence and mortality in a prospective study of middle-aged menD. M. Morens, J. W. Davis, A. Grandinetti et al.Neurology, April 01, 1996 -
Articles
Excess incidence of ALS in young Gulf War veteransRobert W. Haley et al.Neurology, September 22, 2003 -
Articles
Changing epidemiology of Parkinson’s disease in southwestern FinlandAnne-Maria Kuopio, Reijo J. Marttila, Hans Helenius et al.Neurology, January 01, 1999 -
Article
Premature mortality in active convulsive epilepsy in rural KenyaCauses and associated factorsAnthony K. Ngugi, Christian Bottomley, Gregory Fegan et al.Neurology, January 17, 2014